Pembrolizumab: all 1,753 studies that test it
Page 2 of 18. Open to participants first (418), then studies with results posted, then the rest; newest registration first within each.
- Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) PatientsRecruitingNCT07176312Phase 2
- Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care ImmunotherapiesRecruitingNCT07174453Phase 3
- CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCsRecruitingNCT07172256Phase 2
- M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid TumorsRecruitingNCT07166601Phase 1
- Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract CancerNot yet recruitingNCT07151872Phase 2
- A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)RecruitingNCT07136545Phase 1/2
- Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal CarcinomaNot yet recruitingNCT07129772Phase 2
- A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsRecruitingNCT07123415Phase 1
- Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid TumorsRecruitingNCT07095868Phase 1/2
- Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate CancerNot yet recruitingNCT07090369Phase 1
- A Study of Pembrolizumab in People With Ultra-Rare SarcomasRecruitingNCT07089992Phase 2
- Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder CancersRecruitingNCT07087860Phase 2
- Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal AdenocarcinomaRecruitingNCT07082439Phase 2
- Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT TrialRecruitingNCT07061964Phase 2
- A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial CancerRecruitingNCT07054567Phase 2
- Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate CancerRecruitingNCT07027124Phase 2
- ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin LymphomaRecruitingNCT07021989Phase 2
- An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction AdenocarcinomaRecruitingNCT07018570Phase 2
- GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung CancerRecruitingNCT07017829Phase 2
- ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and RadiationNot yet recruitingNCT07015853Phase 2
- Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruitingNCT07010393Phase 4
- Pembrolizumab for Advanced Cutaneous Sarcomas Not Including AngiosarcomaRecruitingNCT07007273Phase 2
- JSKN003 Combined Treatment of HER2-positive Gastric CancerNot yet recruitingNCT06998771Phase 2
- A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid MalignanciesRecruitingNCT06994806Phase 1
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerRecruitingNCT06989112Phase 3
- A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal CancerRecruitingNCT06962787Phase 2
- Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06960395Phase 1
- A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RecruitingNCT06952504Phase 3
- Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung CancerNot yet recruitingNCT06951399Phase 2
- Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaNot yet recruitingNCT06942767Phase 2
- IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)RecruitingNCT06940440Phase 1
- Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal CholangiocarcinomaRecruitingNCT06923475Phase 2/3
- Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin LymphomaNot yet recruitingNCT06916416Phase 2
- Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCCRecruitingNCT06912087Phase 1
- A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor PatientsRecruitingNCT06911827Phase 1/2
- ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung CancerRecruitingNCT06902272Phase 2
- Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for AngiosarcomaRecruitingNCT06898970Phase 2
- A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell CarcinomaNot yet recruitingNCT06894459Phase 2
- Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerRecruitingNCT06890598Phase 3
- TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell CancerRecruitingNCT06868433Phase 1
- Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma SubtypeRecruitingNCT06863402Phase 2
- Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal CancerRecruitingNCT06846268Phase 2
- NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer PatientsRecruitingNCT06845319Phase 2
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)RecruitingNCT06841354Phase 3
- A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)RecruitingNCT06822543Phase 2
- PD-1 Inhibitors Maintenance for cHL Post-autoHCTRecruitingNCT06812858Phase 2
- Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder CancerRecruitingNCT06809140Phase 2
- Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical AdenocarcinomaNot yet recruitingNCT06805864Phase 2
- Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid TumorsRecruitingNCT06795412Phase 1/2
- Pembrolizumab and Pemetrexed for Progressive ChordomaRecruitingNCT06794645Phase 2
- A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCCNot yet recruitingNCT06793761Phase 2
- A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid TumorsRecruitingNCT06789172Phase 1
- Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsRecruitingNCT06772623Phase 1/2
- Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory MelanomaRecruitingNCT06771544Phase 2
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC TrialRecruitingNCT06770582Phase 2
- Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI TrialRecruitingNCT06764095Phase 4
- A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLCRecruitingNCT06754644Phase 3
- Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck CancerRecruitingNCT06736379Phase 1
- Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Phase 3
- Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent ImmunotherapyRecruitingNCT06731270Phase 2
- Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid TumorsRecruitingNCT06724016Phase 1
- A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic TherapiesRecruitingNCT06719362Phase 1
- Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract CancerRecruitingNCT06708858Phase 2
- Pembrolizumab in Combination with Flutamide Treatment for Recurrence / Metastasis HNSCCNot yet recruitingNCT06694350Phase 2
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
- Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma PatientsRecruitingNCT06673628Phase 2
- Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer.RecruitingNCT06670911Phase 2
- Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial TreatmentRecruitingNCT06669572Phase 2
- NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV MelanomaRecruitingNCT06651151Phase 2
- Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.Not yet recruitingNCT06646445Phase 2
- TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and MeningiomasRecruitingNCT06640582Phase 1/2
- Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical OutcomesRecruitingNCT06640283Phase 2
- Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast CancerRecruitingNCT06637306Early Phase 1
- Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP TrialRecruitingNCT06636734Phase 2
- A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory MelanomaRecruitingNCT06624644Phase 2/3
- A Study to Evaluate ALN-BCAT in Patients With Hepatocellular CarcinomaRecruitingNCT06600321Phase 1
- Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial OriginRecruitingNCT06576037Phase 1
- OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd TrialRecruitingNCT06558214Phase 2
- EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed GlioblastomaRecruitingNCT06556563Phase 3
- A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)RecruitingNCT06551142Phase 1
- Ixovex-1 Single Agent and Combination TherapyRecruitingNCT06549946Phase 1/2
- Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)RecruitingNCT06545682Phase 1
- External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical CancerRecruitingNCT06543576Phase 1/2
- TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung CancerRecruitingNCT06538012Phase 1/2
- TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast CancerRecruitingNCT06532812Phase 1/2
- TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal CancerRecruitingNCT06532799Phase 1/2
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerRecruitingNCT06524544Phase 3
- Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With MedulloblastomaRecruitingNCT06514898Phase 1
- ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian CancersRecruitingNCT06513624Phase 1
- Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal CancerRecruitingNCT06493019Phase 2
- High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast CancerRecruitingNCT06492759Phase 2
- Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.RecruitingNCT06492421Phase 2
- Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.RecruitingNCT06492408Phase 2
- A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHLRecruitingNCT06484920Phase 2
- An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06480552Phase 1
- Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast CancerRecruitingNCT06472583Phase 2
- Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder CancerRecruitingNCT06470282Phase 1/2
- Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior ImmunotherapyRecruitingNCT06439836Phase 1
- Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated SarcomasRecruitingNCT06422806Phase 3
- Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:Not yet recruitingNCT06411171Phase 3